Preservation of the ischemic canine myocardium: a comparison of hypothermia, lidoflazine, and ketanserin.
The purpose of this study was to determine whether ketanserin protects the globally ischemic canine heart and whether such protection, if present, is independent of that provided by hypothermia or calcium channel blockade with lidoflazine. Forty mongrel dogs, anesthetized with halothane, were divided into eight groups of five and subjected to one hour of global myocardial ischemia during hypothermic (30 degrees C; groups 1 to 4) or normothermic (37 degrees C; groups 5 to 8) cardiopulmonary bypass (CPB). Dogs in groups 1 and 5 served as controls with respect to prebypass myocardial protective therapy, and received only placebo (a normal saline bolus) prior to CPB. Before bypass, dogs in groups 2 and 6 received lidoflazine, 1.25 mg/kg intravenously (IV); those in groups 3 and 7 received ketanserin, 5 mg IV bolus, followed by a continuous infusion at 33 microg/min during bypass. Animals in groups 4 and 8 were given both lidoflazine and ketanserin according to the dosing schedules above. No type of pharmacologic or mechanical cardiovascular support was provided after termination of CPB. Postbypass hemodynamic performance and survival of the unsupported animal were assumed to reflect the degree of myocardial protection during CPB. One minute after bypass, mean arterial pressure and cardiac output were decreased in all groups. Cardiac output was lower in groups 5 to 8 (normothermic CPB) than in groups 1 to 4 (hypothermic CPB). After CPB, left ventricular filling pressures were elevated in all groups kept normothermic and in group 3 (hypothermic CPB plus ketanserin). By 15 minutes after CPB, there were no survivors in groups 5, 7, and 8. Sixty percent of animals in group 6 (normothermic CPB plus lidoflazine) survived to the end of the study. Relative odds of survival were increased 110-fold by hypothermia and sevenfold by lidoflazine. Conversely, treatment with ketanserin was associated with an increased likelihood of nonsurvival. It is concluded that, at the doses studied, ketanserin does not protect the canine myocardium against ischemic injury and may exert a detrimental effect when combined with calcium channel blockade in this setting.
Clark
N J
NJ
Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City 84132, USA.
Port
J D
JD
McJames
S W
SW
Stockham
R J
RJ
Stanley
T H
TH
Pace
N L
NL
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002302:Cardiac Output / Q000187:drug effects; D002315:Cardiopulmonary Bypass / Q000379:methods; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004285:Dogs; D005260:Female; D007036:Hypothermia, Induced / Q000379:methods / Q000706:statistics & numerical data*; D007650:Ketanserin / Q000627:therapeutic use*; D008013:Lidoflazine / Q000627:therapeutic use*; D008297:Male; D017202:Myocardial Ischemia / Q000628:therapy*; D016017:Odds Ratio; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D016019:Survival Analysis; D014655:Vascular Resistance / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D007650:Ketanserin; D008013:Lidoflazine